Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Erlotinib vs Gefitinib in EGFR-mutant NSCLC
NCT01955421Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01955421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01955421.